<p>德意志銀行在最近向證券交易委員會提交的 13F 表格中表示，在第一季度將其在百時美施貴寶公司（NYSE:BMY - 免費報告）的股份增持了 0.1%。該基金在此期間購買了 13,995 股後，持有該生物製藥公司 9,580,456 股股票。截至最近的 SEC 文件，德意志銀行持有的百時美施貴寶股份約佔 0.47%，價值 584,312,000 美元。</p>
<ul>
<li>不要被反彈所迷惑：市場風暴尚未結束</li>
</ul>
<p>其他一些對沖基金和機構投資者也調整了對 BMY 的持股。Pinney &amp; Scofield Inc.在第四季度購買了價值約 25,000 美元的百時美施貴寶新股份。Park Square Financial Group LLC 在第四季度購買了價值約 26,000 美元的百時美施貴寶新股份。Global Wealth Strategies &amp; Associates 在第一季度將其在百時美施貴寶的持股增加了 137.5%。Global Wealth Strategies &amp; Associates 現在擁有 475 股該生物製藥公司的股票，價值 29,000 美元，此前在此期間又購買了 275 股。Transce3nd LLC 在第四季度購買了價值約 28,000 美元的百時美施貴寶新股份。最後，Harel Insurance Investments &amp; Financial Services Ltd.在第一季度獲得了價值 31,000 美元的百時美施貴寶新股份。機構投資者和對沖基金持有該公司 76.41% 的股份。</p>
<p>獲取 <strong>百時美施貴寶</strong> 的提醒：</p>
<h2>百時美施貴寶價格表現</h2>
<p>週四，NYSE BMY 的開盤價為 44.82 美元。該股票的 50 日簡單移動平均線為 47.41 美元，200 日簡單移動平均線為 52.06 美元。百時美施貴寶公司的 12 個月最低價為 42.96 美元，最高價為 63.33 美元。該股票的市值為 912.4 億美元，市盈率為 18.07，市盈增長比率為 2.35，貝塔係數為 0.36。該公司的債務與股本比率為 2.54，速動比率為 1.11，流動比率為 1.21。</p>
<ul>
<li>MarketBeat 週迴顧 – 02/03 - 02/07</li>
</ul>
<p>百時美施貴寶（NYSE:BMY - 獲取免費報告）最近在 7 月 31 日發佈了季度財報。這家生物製藥公司報告的季度每股收益為 1.46 美元，超出分析師一致預期的 1.07 美元，超過 0.39 美元。百時美施貴寶的股本回報率為 80.04%，淨利潤率為 10.58%。該公司在本季度的收入為 122.7 億美元，而分析師預期為 113.2 億美元。在去年同期，該公司每股收益為 2.07 美元。該公司的季度收入較去年同期增長了 0.6%。研究分析師預計百時美施貴寶公司今年將發佈 6.74 美元的每股收益。</p>
<h2>百時美施貴寶宣佈分紅</h2>
<p>該公司最近還宣佈了季度分紅，已於 8 月 1 日（星期五）支付。7 月 3 日（星期四）登記在冊的股東獲得了 0.62 美元的分紅。這代表着每年 2.48 美元的分紅和 5.5% 的收益率。除息日期為 7 月 3 日（星期四）。百時美施貴寶的分紅支付比率（DPR）目前為 100.00%。</p>
<h2>華爾街分析師觀點</h2>
<ul>
<li>百時美施貴寶的疲軟指引可能創造了機會</li>
</ul>
<p>BMY 已成為多份研究分析師報告的主題。Jefferies Financial Group 在 4 月 23 日的報告中將百時美施貴寶的目標價從 70.00 美元下調至 68.00 美元，並對該股票給予 “買入” 評級。Piper Sandler 在 4 月 22 日的研究報告中啓動了對百時美施貴寶的覆蓋，給予 “增持” 評級，目標價為 65.00 美元。Argus 在 4 月 25 日的研究報告中將百時美施貴寶的股票評級上調至 “持有”。Wall Street Zen 在 6 月 6 日的研究報告中將百時美施貴寶的股票評級從 “強烈買入” 下調至 “買入”。最後，Cantor Fitzgerald 在 4 月 22 日的研究報告中重申了 “中性” 評級，並將百時美施貴寶的目標價設定為 55.00 美元。一位分析師對該股票給予了賣出評級，十五位給予了持有評級，五位給予了買入評級，一位給予了強烈買入評級。根據 MarketBeat.com 的數據，百時美施貴寶的平均評級為 “持有”，平均目標價為 56.38 美元。</p>
<p><strong>查看我們對 BMY 的最新分析</strong></p>
<h2>百時美施貴寶簡介</h2>
<p>（免費報告）</p>
<p>百時美施貴寶公司在全球範圍內發現、開發、許可、製造、營銷、分銷和銷售生物製藥產品。它提供用於血液學、腫瘤學、心血管、免疫學、纖維化和神經科學疾病的產品。該公司的產品包括 Eliquis，用於降低非瓣膜性房顫中中風/全身栓塞的風險，以及用於治療深靜脈血栓/肺栓塞；Opdivo 用於各種抗癌適應症，包括膀胱癌、血液癌、結直腸癌、頭頸癌、腎細胞癌、肝細胞癌、肺癌、黑色素瘤、胸膜間皮瘤、胃癌和食道癌；Pomalyst/Imnovid 用於多發性骨髓瘤；Orencia 用於活動性類風濕關節炎和銀屑病關節炎；Sprycel 用於治療費城染色體陽性慢性髓性白血病。</p>
<h2>閲讀更多</h2>
<ul>
<li>我們更看好的五隻股票，勝過百時美施貴寶</li>
<li>羅素 2000 指數，投資者如何利用它進行盈利交易</li>
<li>RSI 股票在第二季度暴漲 22%——PENN 能否匹配這種勢頭？</li>
<li>理解看漲期權交易量對成功期權交易的重要性</li>
<li>DigitalOcean 的專注如何推動爆炸性增長</li>
<li>如何投資藍籌股</li>
<li>Celsius 股票能否繼續保持其勢頭？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在百時美施貴寶嗎？</h2>
<p>在考慮百時美施貴寶之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而百時美施貴寶並不在名單上。</p>
<p>雖然百時美施貴寶目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

百時美施貴寶

<p>德意志銀行（Deutsche Bank AG）在第一季度將其在百時美施貴寶（Bristol Myers Squibb Company，NYSE:BMY）的持股比例增加了 0.1%，目前持有 9,580,456 股，價值約為 5.8431 億美元。其他機構投資者也調整了他們的持股。百時美施貴寶報告的季度每股收益（EPS）為 1.46 美元，超出預期，收入為 122.7 億美元。該公司宣佈季度股息為 0.62 美元，收益率為 5.5%。分析師對該股票的評級不一，平均目標價為 56.38 美元，普遍評級為 “持有”</p>

<p>Deutsche Bank AG grew its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 0.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The fund owned 9,580,456 shares of the biopharmaceutical company's stock after purchasing an additional 13,995 shares during the period. Deutsche Bank AG owned about 0.47% of Bristol Myers Squibb worth $584,312,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>德意志銀行在最近向證券交易委員會提交的 13F 表格中表示，在第一季度將其在百時美施貴寶公司（NYSE:BMY - 免費報告）的股份增持了 0.1%。該基金在此期間購買了 13,995 股後，持有該生物製藥公司 9,580,456 股股票。截至最近的 SEC 文件，德意志銀行持有的百時美施貴寶股份約佔 0.47%，價值 584,312,000 美元。</p>
</div><ul>
<li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>不要被反彈所迷惑：市場風暴尚未結束</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors have also modified their holdings of BMY. Pinney &amp; Scofield Inc. purchased a new stake in Bristol Myers Squibb during the fourth quarter valued at about $25,000. Park Square Financial Group LLC purchased a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at approximately $26,000. Global Wealth Strategies &amp; Associates boosted its stake in Bristol Myers Squibb by 137.5% in the 1st quarter. Global Wealth Strategies &amp; Associates now owns 475 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 275 shares during the period. Transce3nd LLC purchased a new position in Bristol Myers Squibb during the 4th quarter worth approximately $28,000. Finally, Harel Insurance Investments &amp; Financial Services Ltd. acquired a new stake in Bristol Myers Squibb during the 1st quarter valued at $31,000. Institutional investors and hedge funds own 76.41% of the company's stock.</p>
<div class="lb-trans"><p>其他一些對沖基金和機構投資者也調整了對 BMY 的持股。Pinney &amp; Scofield Inc.在第四季度購買了價值約 25,000 美元的百時美施貴寶新股份。Park Square Financial Group LLC 在第四季度購買了價值約 26,000 美元的百時美施貴寶新股份。Global Wealth Strategies &amp; Associates 在第一季度將其在百時美施貴寶的持股增加了 137.5%。Global Wealth Strategies &amp; Associates 現在擁有 475 股該生物製藥公司的股票，價值 29,000 美元，此前在此期間又購買了 275 股。Transce3nd LLC 在第四季度購買了價值約 28,000 美元的百時美施貴寶新股份。最後，Harel Insurance Investments &amp; Financial Services Ltd.在第一季度獲得了價值 31,000 美元的百時美施貴寶新股份。機構投資者和對沖基金持有該公司 76.41% 的股份。</p>
</div><p>Get <strong>Bristol Myers Squibb</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>百時美施貴寶</strong> 的提醒：</p>
</div><h2>Bristol Myers Squibb Price Performance</h2>
<div class="lb-trans"><h2>百時美施貴寶價格表現</h2>
</div><p>NYSE BMY opened at $44.82 on Thursday. The stock has a 50-day simple moving average of $47.41 and a 200 day simple moving average of $52.06. Bristol Myers Squibb Company has a twelve month low of $42.96 and a twelve month high of $63.33. The stock has a market capitalization of $91.24 billion, a PE ratio of 18.07, a P/E/G ratio of 2.35 and a beta of 0.36. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21.</p>
<div class="lb-trans"><p>週四，NYSE BMY 的開盤價為 44.82 美元。該股票的 50 日簡單移動平均線為 47.41 美元，200 日簡單移動平均線為 52.06 美元。百時美施貴寶公司的 12 個月最低價為 42.96 美元，最高價為 63.33 美元。該股票的市值為 912.4 億美元，市盈率為 18.07，市盈增長比率為 2.35，貝塔係數為 0.36。該公司的債務與股本比率為 2.54，速動比率為 1.11，流動比率為 1.21。</p>
</div><ul>
<li>MarketBeat Week in Review – 02/03 - 02/07</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 02/03 - 02/07</li>
</ul>
</div><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, topping analysts' consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%. The company had revenue of $12.27 billion during the quarter, compared to analyst estimates of $11.32 billion. During the same period in the previous year, the company earned $2.07 earnings per share. The company's quarterly revenue was up .6% compared to the same quarter last year. Research analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.</p>
<div class="lb-trans"><p>百時美施貴寶（NYSE:BMY - 獲取免費報告）最近在 7 月 31 日發佈了季度財報。這家生物製藥公司報告的季度每股收益為 1.46 美元，超出分析師一致預期的 1.07 美元，超過 0.39 美元。百時美施貴寶的股本回報率為 80.04%，淨利潤率為 10.58%。該公司在本季度的收入為 122.7 億美元，而分析師預期為 113.2 億美元。在去年同期，該公司每股收益為 2.07 美元。該公司的季度收入較去年同期增長了 0.6%。研究分析師預計百時美施貴寶公司今年將發佈 6.74 美元的每股收益。</p>
</div><h2>Bristol Myers Squibb Announces Dividend</h2>
<div class="lb-trans"><h2>百時美施貴寶宣佈分紅</h2>
</div><p>The business also recently declared a quarterly dividend, which was paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd were given a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.5%. The ex-dividend date was Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 100.00%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了季度分紅，已於 8 月 1 日（星期五）支付。7 月 3 日（星期四）登記在冊的股東獲得了 0.62 美元的分紅。這代表着每年 2.48 美元的分紅和 5.5% 的收益率。除息日期為 7 月 3 日（星期四）。百時美施貴寶的分紅支付比率（DPR）目前為 100.00%。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><ul>
<li>Weak Guidance from Bristol-Myers Could Be Creating an Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>百時美施貴寶的疲軟指引可能創造了機會</li>
</ul>
</div><p>BMY has been the topic of a number of research analyst reports. Jefferies Financial Group lowered their price target on Bristol Myers Squibb from $70.00 to $68.00 and set a &#34;buy&#34; rating on the stock in a report on Wednesday, April 23rd. Piper Sandler initiated coverage on Bristol Myers Squibb in a research note on Tuesday, April 22nd. They set an &#34;overweight&#34; rating and a $65.00 target price on the stock. Argus raised shares of Bristol Myers Squibb to a &#34;hold&#34; rating in a research report on Friday, April 25th. Wall Street Zen downgraded shares of Bristol Myers Squibb from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Friday, June 6th. Finally, Cantor Fitzgerald reissued a &#34;neutral&#34; rating and set a $55.00 target price on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. One analyst has rated the stock with a sell rating, fifteen have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb has an average rating of &#34;Hold&#34; and an average price target of $56.38.</p>
<div class="lb-trans"><p>BMY 已成為多份研究分析師報告的主題。Jefferies Financial Group 在 4 月 23 日的報告中將百時美施貴寶的目標價從 70.00 美元下調至 68.00 美元，並對該股票給予 “買入” 評級。Piper Sandler 在 4 月 22 日的研究報告中啓動了對百時美施貴寶的覆蓋，給予 “增持” 評級，目標價為 65.00 美元。Argus 在 4 月 25 日的研究報告中將百時美施貴寶的股票評級上調至 “持有”。Wall Street Zen 在 6 月 6 日的研究報告中將百時美施貴寶的股票評級從 “強烈買入” 下調至 “買入”。最後，Cantor Fitzgerald 在 4 月 22 日的研究報告中重申了 “中性” 評級，並將百時美施貴寶的目標價設定為 55.00 美元。一位分析師對該股票給予了賣出評級，十五位給予了持有評級，五位給予了買入評級，一位給予了強烈買入評級。根據 MarketBeat.com 的數據，百時美施貴寶的平均評級為 “持有”，平均目標價為 56.38 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on BMY</strong></p>
<div class="lb-trans"><p><strong>查看我們對 BMY 的最新分析</strong></p>
</div><h2>Bristol Myers Squibb Profile</h2>
<div class="lb-trans"><h2>百時美施貴寶簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.</p>
<div class="lb-trans"><p>百時美施貴寶公司在全球範圍內發現、開發、許可、製造、營銷、分銷和銷售生物製藥產品。它提供用於血液學、腫瘤學、心血管、免疫學、纖維化和神經科學疾病的產品。該公司的產品包括 Eliquis，用於降低非瓣膜性房顫中中風/全身栓塞的風險，以及用於治療深靜脈血栓/肺栓塞；Opdivo 用於各種抗癌適應症，包括膀胱癌、血液癌、結直腸癌、頭頸癌、腎細胞癌、肝細胞癌、肺癌、黑色素瘤、胸膜間皮瘤、胃癌和食道癌；Pomalyst/Imnovid 用於多發性骨髓瘤；Orencia 用於活動性類風濕關節炎和銀屑病關節炎；Sprycel 用於治療費城染色體陽性慢性髓性白血病。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>閲讀更多</h2>
</div><ul>
<li>Five stocks we like better than Bristol Myers Squibb</li>
<li>Russell 2000 Index, How Investors Use it For Profitable Trading</li>
<li>RSI Stock Soars 22% On Q2 Blowout—Will PENN Match the Momentum?</li>
<li>Why Understanding Call Option Volume is Essential to Successful Options Trading</li>
<li>How DigitalOcean's Focus Is Fueling Explosive Growth</li>
<li>How to Invest in Blue Chip Stocks</li>
<li>Can Celsius Stock Keep Its Momentum Going Any Longer?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過百時美施貴寶</li>
<li>羅素 2000 指數，投資者如何利用它進行盈利交易</li>
<li>RSI 股票在第二季度暴漲 22%——PENN 能否匹配這種勢頭？</li>
<li>理解看漲期權交易量對成功期權交易的重要性</li>
<li>DigitalOcean 的專注如何推動爆炸性增長</li>
<li>如何投資藍籌股</li>
<li>Celsius 股票能否繼續保持其勢頭？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=BMY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在百時美施貴寶嗎？</h2>
</div><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮百時美施貴寶之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而百時美施貴寶並不在名單上。</p>
</div><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然百時美施貴寶目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

德意志銀行股份公司持有百時美施貴寶公司（NYSE:BMY）價值 5.8431 億美元的股票